Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism

Clinical Question

In patient’s with intermediate-risk PE does the addition of fibrinolytic therapy to standard anticoagulation therapy improve mortality and/or hemodynamic decompensation in the first 7 days.

Bottom Line

Patient’s with intermediate-risk PE who received fibrinolytic therapy in combination with standard anticoagulation had a statistically significant reduction in hemodynamic instability within 7 days as well as a statistically significant increase in major bleeding events.